States take legal action as 23andMe attempts to sell customer genetic information amid bankruptcy

Twenty-seven states and the District of Columbia have taken legal action against bankrupt genetic testing company 23andMe, challenging its plan to sell customer genetic data without explicit consent during Chapter 11 proceedings. The states argue that 23andMe cannot sell customers' genetic information without first obtaining express informed consent, while 23andMe maintains the sale is permitted under its privacy policies and applicable law, with potential buyers Regeneron Pharmaceuticals and TTAM Research Institute committed to abiding by these policies. This legal challenge introduces uncertainty surrounding the sale of 23andMe's assets, valued between $100 million and $500 million, and raises concerns about the future handling of sensitive customer data.

Analysis

Genetic testing company 23andMe, currently undergoing Chapter 11 bankruptcy proceedings initiated in March, faces a significant legal impediment to its asset sale process. Twenty-seven states and the District of Columbia have filed a lawsuit asserting that 23andMe cannot sell customer genetic information without obtaining explicit, informed consent from each individual, a stance directly challenging the company's plans to monetize these assets, estimated to be worth between $100 million and $500 million. 23andMe, however, maintains through a spokesperson that its privacy policies and applicable laws permit such a sale, and that any acquiring party—such as initial successful bidder Regeneron Pharmaceuticals (REGN) with a $256 million offer or the subsequent higher bidder TTAM Research Institute ($305 million)—would be bound by these existing policies. This legal intervention, underscored by a 'strongly negative' general sentiment score of -0.65 and an 'uncertain' tone from market signals, introduces considerable uncertainty over the valuation and disposition of 23andMe's assets, specifically jeopardizing the monetization of its extensive customer genetic database. The outcome of this dispute, overseen by the U.S. Bankruptcy Court, will be pivotal for 23andMe's creditors and could establish important precedents regarding data privacy and consent in bankruptcy sales, particularly within the biotech and data-intensive sectors.

Key Decisions for Investors

• Investors tracking Regeneron Pharmaceuticals (REGN) should closely monitor the legal proceedings involving 23andMe, as the outcome will directly affect the viability, terms, and potential liabilities associated with its bid for 23andMe's assets.
• Stakeholders with an interest in 23andMe's bankruptcy must acknowledge the heightened risk profile, as this legal challenge could materially reduce asset recovery values or significantly extend the timeline of the bankruptcy resolution.
• Participants in the broader biotech, healthcare, and data brokerage industries should consider the implications of this case as a potential bellwether for increased regulatory scrutiny and legal activism concerning the commercialization of sensitive personal data, especially during M&A and restructuring events.